Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211124 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kunna Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Microbiology Section, A-LIFE and AIMMS, Faculty of Science, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Verapamil, Antitubercular Agents, Mycobacterium tuberculosis, Drug Resistance, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council.
Abstract (Originalsprache)
The emergence of drug resistance remains a major challenge in the treatment of tuberculosis and other mycobacterial infections. To combat the rise in resistance, strategies that reduce the frequency of resistance mutations are urgently needed. Verapamil is a small-molecule compound that can enhance the potency of companion drugs in combination regimen. Here, we investigate if verapamil can decrease the resistance frequency of antimycobacterial drugs. The results show that verapamil significantly reduces the resistance frequency of multiple antimycobacterial agents, including the DNA gyrase inhibitor moxifloxacin, the protein synthesis inhibitor streptomycin, and the RNA polymerase inhibitor rifampicin in Mycobacterium smegmatis. The presence of point mutations in the target was confirmed for moxifloxacin-resistant M. smegmatis. Suppression of resistance evolution against moxifloxacin by verapamil was also found in the slow-growing, pathogenic mycobacteria M. avium and M. tuberculosis. Real-time qPCR analysis in M. smegmatis showed that verapamil treatment downregulates the expression of multiple efflux pump genes and upregulates DNA repair genes. These findings suggest that verapamil exerts a dual role by interfering with efflux pump functionality and by reducing the probability of chromosomal mutations. The combination of these properties may underlie the promise of verapamil as adjuvant to enhance the effectiveness of current antimycobacterial chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Microbiology Section, A-LIFE and AIMMS, Faculty of Science, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands.
- Medical Microbiology and Infection Control (MMI), Amsterdam University Medical Center Location VUmc, 1081 HZ Amsterdam, The Netherlands.
- Amsterdam Institute for Immunology & Infectious Diseases, Amsterdam University Medical Center Location VUmc, 1081 HZ Amsterdam, The Netherlands.
ORCID-Profile: Coenraad P Kuijl, Yuval Mulla
Förderung
- China Scholarship Council
Zitieren
APA
Liu, K., Buitenhek, E., Kuijl, C. P., Mulla, Y., Luirink, J., & Bald, D. (2025). Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211124
Vancouver
Liu K, Buitenhek E, Kuijl CP, Mulla Y, Luirink J, Bald D. Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211124
BibTeX
@article{Liu2025,
author = {Liu, Kunna and Buitenhek, Elise and Kuijl, Coenraad P and Mulla, Yuval and Luirink, Joen and Bald, Dirk},
title = {Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211124}
}
EUVIMED